192 related articles for article (PubMed ID: 37158894)
1. KRAS, MYC, and ARF6: inseparable relationships cooperatively promote cancer malignancy and immune evasion.
Sabe H
Cell Commun Signal; 2023 May; 21(1):106. PubMed ID: 37158894
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of mutant KRAS-driven overexpression of ARF6 and MYC by an eIF4A inhibitor drug improves the effects of anti-PD-1 immunotherapy for pancreatic cancer.
Hashimoto A; Handa H; Hata S; Tsutaho A; Yoshida T; Hirano S; Hashimoto S; Sabe H
Cell Commun Signal; 2021 May; 19(1):54. PubMed ID: 34001163
[TBL] [Abstract][Full Text] [Related]
3. ARF6 and AMAP1 are major targets of
Hashimoto S; Furukawa S; Hashimoto A; Tsutaho A; Fukao A; Sakamura Y; Parajuli G; Onodera Y; Otsuka Y; Handa H; Oikawa T; Hata S; Nishikawa Y; Mizukami Y; Kodama Y; Murakami M; Fujiwara T; Hirano S; Sabe H
Proc Natl Acad Sci U S A; 2019 Aug; 116(35):17450-17459. PubMed ID: 31399545
[TBL] [Abstract][Full Text] [Related]
4. High expression of AMAP1, an ARF6 effector, is associated with elevated levels of PD-L1 and fibrosis of pancreatic cancer.
Tsutaho A; Hashimoto A; Hashimoto S; Hata S; Kachi S; Hirano S; Sabe H
Cell Commun Signal; 2020 Jun; 18(1):101. PubMed ID: 32580737
[TBL] [Abstract][Full Text] [Related]
5. ADP-Ribosylation Factor 6 Pathway Acts as a Key Executor of Mesenchymal Tumor Plasticity.
Hashimoto A; Hashimoto S
Int J Mol Sci; 2023 Oct; 24(19):. PubMed ID: 37834383
[TBL] [Abstract][Full Text] [Related]
6. PIN1 Maintains Redox Balance via the c-Myc/NRF2 Axis to Counteract Kras-Induced Mitochondrial Respiratory Injury in Pancreatic Cancer Cells.
Liang C; Shi S; Liu M; Qin Y; Meng Q; Hua J; Ji S; Zhang Y; Yang J; Xu J; Ni Q; Li M; Yu X
Cancer Res; 2019 Jan; 79(1):133-145. PubMed ID: 30355620
[TBL] [Abstract][Full Text] [Related]
7. Targeting eIF4A-Dependent Translation of KRAS Signaling Molecules.
Singh K; Lin J; Lecomte N; Mohan P; Gokce A; Sanghvi VR; Jiang M; Grbovic-Huezo O; Burčul A; Stark SG; Romesser PB; Chang Q; Melchor JP; Beyer RK; Duggan M; Fukase Y; Yang G; Ouerfelli O; Viale A; de Stanchina E; Stamford AW; Meinke PT; Rätsch G; Leach SD; Ouyang Z; Wendel HG
Cancer Res; 2021 Apr; 81(8):2002-2014. PubMed ID: 33632898
[TBL] [Abstract][Full Text] [Related]
8. Translation control of the immune checkpoint in cancer and its therapeutic targeting.
Xu Y; Poggio M; Jin HY; Shi Z; Forester CM; Wang Y; Stumpf CR; Xue L; Devericks E; So L; Nguyen HG; Griselin A; Gordan JD; Umetsu SE; Reich SH; Worland ST; Asthana S; Barna M; Webster KR; Cunningham JT; Ruggero D
Nat Med; 2019 Feb; 25(2):301-311. PubMed ID: 30643286
[TBL] [Abstract][Full Text] [Related]
9. Oncogenic RAS promotes MYC protein stability by upregulating the expression of the inhibitor of apoptosis protein family member Survivin.
Chang WH; Liu Y; Hammes EA; Bryant KL; Cerione RA; Antonyak MA
J Biol Chem; 2023 Feb; 299(2):102842. PubMed ID: 36581205
[TBL] [Abstract][Full Text] [Related]
10. Application of a MYC degradation screen identifies sensitivity to CDK9 inhibitors in KRAS-mutant pancreatic cancer.
Blake DR; Vaseva AV; Hodge RG; Kline MP; Gilbert TSK; Tyagi V; Huang D; Whiten GC; Larson JE; Wang X; Pearce KH; Herring LE; Graves LM; Frye SV; Emanuele MJ; Cox AD; Der CJ
Sci Signal; 2019 Jul; 12(590):. PubMed ID: 31311847
[TBL] [Abstract][Full Text] [Related]
11. KRAS drives immune evasion in a genetic model of pancreatic cancer.
Ischenko I; D'Amico S; Rao M; Li J; Hayman MJ; Powers S; Petrenko O; Reich NC
Nat Commun; 2021 Mar; 12(1):1482. PubMed ID: 33674596
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic effects of an anti-Myc drug on mouse pancreatic cancer.
Stellas D; Szabolcs M; Koul S; Li Z; Polyzos A; Anagnostopoulos C; Cournia Z; Tamvakopoulos C; Klinakis A; Efstratiadis A
J Natl Cancer Inst; 2014 Dec; 106(12):. PubMed ID: 25306215
[TBL] [Abstract][Full Text] [Related]
13. ARF6, induced by mutant Kras, promotes proliferation and Warburg effect in pancreatic cancer.
Liang C; Qin Y; Zhang B; Ji S; Shi S; Xu W; Liu J; Xiang J; Liang D; Hu Q; Ni Q; Yu X; Xu J
Cancer Lett; 2017 Mar; 388():303-311. PubMed ID: 28025100
[TBL] [Abstract][Full Text] [Related]
14. Frequent overexpression of AMAP1, an Arf6 effector in cell invasion, is characteristic of the MMTV-PyMT rather than the MMTV-Neu human breast cancer model.
Otsuka Y; Oikawa T; Yoshino H; Hashimoto S; Handa H; Yamamoto H; Hashimoto A; Sabe H
Cell Commun Signal; 2018 Jan; 16(1):1. PubMed ID: 29329590
[TBL] [Abstract][Full Text] [Related]
15. Hyperglycemia enhances pancreatic cancer progression accompanied by elevations in phosphorylated STAT3 and MYC levels.
Sato K; Hikita H; Myojin Y; Fukumoto K; Murai K; Sakane S; Tamura T; Yamai T; Nozaki Y; Yoshioka T; Kodama T; Shigekawa M; Sakamori R; Tatsumi T; Takehara T
PLoS One; 2020; 15(7):e0235573. PubMed ID: 32609742
[TBL] [Abstract][Full Text] [Related]
16. Drugging "undruggable" genes for cancer treatment: Are we making progress?
Duffy MJ; Crown J
Int J Cancer; 2021 Jan; 148(1):8-17. PubMed ID: 32638380
[TBL] [Abstract][Full Text] [Related]
17. MYC- and MIZ1-Dependent Vesicular Transport of Double-Strand RNA Controls Immune Evasion in Pancreatic Ductal Adenocarcinoma.
Krenz B; Gebhardt-Wolf A; Ade CP; Gaballa A; Roehrig F; Vendelova E; Baluapuri A; Eilers U; Gallant P; D'Artista L; Wiegering A; Gasteiger G; Rosenfeldt MT; Bauer S; Zender L; Wolf E; Eilers M
Cancer Res; 2021 Aug; 81(16):4242-4256. PubMed ID: 34145038
[TBL] [Abstract][Full Text] [Related]
18. Kras(G12D) induces EGFR-MYC cross signaling in murine primary pancreatic ductal epithelial cells.
Diersch S; Wirth M; Schneeweis C; Jörs S; Geisler F; Siveke JT; Rad R; Schmid RM; Saur D; Rustgi AK; Reichert M; Schneider G
Oncogene; 2016 Jul; 35(29):3880-6. PubMed ID: 26592448
[TBL] [Abstract][Full Text] [Related]
19. Expression of c-myc and mutation of the KRAS gene in patients with ovarian mucinous tumors.
Li XS; Sun J; He XL
Genet Mol Res; 2015 Sep; 14(3):10752-9. PubMed ID: 26400304
[TBL] [Abstract][Full Text] [Related]
20. KRAS-dependent suppression of MYC enhances the sensitivity of cancer cells to cytotoxic agents.
Ischenko I; Zhi J; Hayman MJ; Petrenko O
Oncotarget; 2017 Mar; 8(11):17995-18009. PubMed ID: 28152508
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
